Posts Tagged: "Gene Quinn"

IPW Webinar: EU Trademarks and Trademarks in Europe: What’s the difference? Why does it matter?

Trademarks are a universal phenomenon and have existed for almost as long as trade itself. Identification symbols that worked as early trademarks have been found on the goods that were traded dating back to as early as 4000 years ago. Although found in virtually every legal system around the world, trademarks are based on national law. Having a trademark in…

IPW Webinar: Saving Money on Patent Prosecution: How Data-driven Modeling Lets You Cut With a Scalpel

Securing a patent in 2021 is a tough job. Courts continue to ask for more disclosure and better claims, and that’s when they aren’t moving the goal posts on patent practitioners. Meanwhile, clients demand flat fee billing and want to pay less every year. But what if there were a way for you to work with clients to show them…

IPW Webinar: The Digital Transformation of Legal Operations: How does your IP team stay competitive post-pandemic?

At the start of the pandemic, few could have predicted the upheaval that would be forthcoming. And while life over the past year has been very different, new opportunities have presented themselves, with many companies and employees embracing a remote workforce. While predictions are always difficult, it seems certain that the post-pandemic economy will look very different, with many employees…

IPW Webinar: Saving the World With Patents: Is the TRIPS Waiver Helping or Hurting?

Innovation is to thank for many of the medicines, treatments, and technologies that help save lives and save the world on a daily basis. From insulin to water treatment, there are innovations everywhere that help make the world a better place. This last year has certainly been one that no one could have seen coming. Intellectual property has played an…

Jury May Pick Royalty Rate from Range Offered in Expert Testimony

Earlier this year, the Federal Circuit issued a precedential decision in Bayer Healthcare LLC v. Baxalta Inc. in which the court affirmed rulings from the District of Delaware finding that Baxalta’s hemophilia treatment Adynovate infringes patent claims owned by Bayer, that the asserted claims were enabled, and that Baxalta did not commit willful infringement as a matter of law. Relating to the question of damages, the court explained that an expert need not select a specific royalty rate for the jury to adopt, and that a jury may adopt any royalty rate within the range offered during testimony by the expert provided the methodology used by the expert is sound.

IPW Webinar: Immunology and the Patentability and Enforcement of Immunotherapies

More than 30 years ago the National Cancer Institute began to explore what was then a heretical idea: a patient’s own immune system could be employed to fight cancer. Today, the resulting field of medicine is called immunotherapy, and common practice in hospitals around the world. It is also a fast-growing field.  Numerous companies have begun studies and filed for…

IPW Webinar: Creating a Patent Landscape Game Plan: Identifying Strategic Threats and Potential Incoming Litigation

Patent landscape monitoring is about so much more than simply identifying white space. For those who engage with strategic purpose, patent landscape monitoring is about competitive intelligence, whether that intelligence presents itself in the form of competitors encroaching upon your marketplace with new products, or copyists who are or likely will be engaging in infringement. In this webinar, the panel…

IPW Webinar: Crystalline/Solid Form Patents in the Life Sciences: Issues in Prosecution and Litigation

In December of 2020, IPWatchdog hosted a webinar discussing the use of and interest in solid-form patents in the pharmaceutical industry. There were many questions during the webinar, and many follow-up inquiries on the “nuts and bolts” of these patents. Issues including prosecution, claim drafting, novelty, obviousness, enablement, non-species claims in a crystalline-form context, claim interpretation and proving infringement. Join…

IPWatchdog LIVE In Person, Conference Set for September 12-14 in Dallas, Texas

We are proud to announce that our much anticipated Conference, postponed several times due to COVID-19, will  take place at the Renaissance Dallas Richardson from September 12-14, 2021. Onsite registration will begin on Sunday, September 12, followed by an opening General Session, and then an Opening Cocktail Reception. A premium will be placed on networking, with two Networking Breakfasts, five Networking Breaks, three Networking Receptions and facilitated one-on-one meetings. We will conclude with an ethics CLE prior to our Closing Reception.

IPW Webinar: Budgeting for IP Costs: Transparency, Accuracy, and Modeling the Future

Costs are an omnipresent concern for those in the intellectual property arena, making IP budgeting is a critical necessity for both IP law firms and in-house IP counsels. Whether for purposes of strategic portfolio decision making, or to address requirements to cut spending, accurate budgeting is essential. Unfortunately, creating IP budgets can be time consuming, and it can be extremely…

IPW Webinar – Facilitating and Augmenting Innovation with Artificial Intelligence

For innovative companies the life blood is having engineers and scientists who produce invention disclosures. Unfortunately, as good as they are at creating, engineers and scientists are generally far less equipped to explain what it is that they have created, which creates an obstacle from the start. As every patent attorney can attest, often invention disclosures lack concrete description at…

Iancu Weighs in on IP Waiver, Critical Role of Patents for SMEs at World IP Day Event

“Property rights are not just good for the economy, they save lives”, Grover Norquist, President of Americans for Tax Reform said, speaking at Innovating the Future: Celebrating 2021 World IP Day, sponsored by the Property Rights Alliance. Norquist would go on to conclude his brief opening remarks by lamenting, “the damage that would be done if some of the critics of intellectual property have their way.” Norquist was implicitly referring to an IP waiver proposal by South Africa and India, which would allow nations to ignore patent rights relating to COVID-19 related innovations, particularly vaccines. This waiver of the Trade-Related Aspects of Intellectual Property Rights (TRIPS) is a truly bad idea, and one addressed head on by Andrei Iancu, senior adviser to the Renewing America Innovation Project at the Center for Strategic and International Studies and former Director of the United States Patent and Trademark Office (USPTO).

IPW Webinar – Exploring the Continuum between Human- and AI-Generated Inventions: How Should Patents and Ownership be Allocated?

With the recent accessibility of big data sets and powerful computing systems, artificial intelligence (AI) is increasingly used across industries to generate predictions. A human is always initially involved to program the model and determine any learning objective, but the model may evolve to generate results not foreseen by the human. If the result is new, non-obvious, and useful, should…

PTAB Masters™ Day Four Features Judge Michel on How the PTAB is Working: ‘When Facts Change, Views Should Change’

The final day of IPWatchdog’s PTAB Masters™ 2021 program kicked off with more than 1,070 registrants and a discussion featuring retired U.S. Court of Appeals for the Federal Circuit Chief Judge Paul Michel, Meredith Addy of AddyHart, and IPWatchdog Founder and CEO Gene Quinn about the many obstacles facing patentees today in light of the Patent Trial and Appeal Board (PTAB) and an overburdened Federal Circuit. Michel said that, a decade after the America Invents Act (AIA) was passed, with the real-world knowledge we now have of the PTAB, “conclusions and practices should change in light of experience. When facts change, views should change.”

Kappos at PTAB Masters™ Day Two: PTAB Problems Arose When It Failed to Evolve

The second day of IPWatchdog’s PTAB Masters™ 2021: “Winning at the PTAB” featured a keynote interview with former U.S. Patent and Trademark Office (USPTO) Director David Kappos, who was at the helm of the agency when the America Invents Act (AIA) was passed. As part of the AIA, Kappos was tasked with developing rules to implement the Patent Trial and Appeal Board (PTAB) and related post grant proceedings, and was chiefly focused on adhering to the unprecedented timelines set for those proceedings in the AIA. “The PTO had never been given strict timelines before,” explained Kappos. “I felt the gravity; I thought, ‘if the public is going to respect the PTO and patents, we have to get on top of the timeframes.’ [I told my team] the goal is going to be to implement within the timeframes 100% of the time.”

Varsity Sponsors

Junior Varsity Sponsors

From IPWatchdog